The refurbishment began in April 2010 and was scheduled to take one year to complete but this was delayed because of the controversy that surrounded the costing and tendering process, our reporter says.
In the process of hurting consumers by playing drug-administration-knows-best, the FDA is costing Merck and Bristol-Myers hundreds of millions of dollars.